PMID- 33072639
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220417
IS  - 2277-9175 (Print)
IS  - 2277-9175 (Electronic)
IS  - 2277-9175 (Linking)
VI  - 9
DP  - 2020
TI  - Prevalence of Helicobacter pylori Infection among Type 2 Diabetes Mellitus.
PG  - 27
LID - 10.4103/abr.abr_248_19 [doi]
LID - 27
AB  - BACKGROUND: Several conducted studies have reported a higher and more frequent 
      Helicobacter pylori infection rate in type 2 diabetes mellitus (T2DM). The aim of 
      this study was to investigate the prevalence and its association between H. 
      pylori infection and T2DM. MATERIALS AND METHODS: A case and control study was 
      conducted based on 529 T2DM patients and 529 control. H. pylori was assessed by 
      Serum anti-H. pylori immunoglobulin G (IgG) and IgA. Furthermore, patients were 
      investigated for fasting blood glucose (FBG) levels, glycosylated hemoglobin 
      (HbA1c), serum cholesterol, and other biochemistry parameters. RESULTS: The 
      findings showed a positive significantly higher antibody titer for H. pylori 
      infection (IgA > 250) in diabetic patients (50.7%) compared to controls (38.2%) 
      (P < 0.001). Similarly, H. pylori infection for IgG > 300 titer was higher in 
      T2DM patients (73.5%) compared to controls 61.8%) (P < 0.001). Further, the mean 
      values were statistically significant diabetes with H. pylori infection for IgG > 
      300 titer and IgA > 250 titer, regarding Vitamin D, HbA1C (P < 0.001), FBG, 
      calcium, creatinine, total cholesterol, LHDL, triglyceride levels, uric acid, 
      bilirubin, thyroid-stimulating hormone (TSH), and systolic and diastolic blood 
      pressure. The diabetic patients showed higher prevalence rate of symptoms than 
      controls included: hypertension (14.3%), vomiting (15.5%), muscular symptoms 
      (35.2%), bloating/distension (13.2%), abdominal pain (17%), nausea (9.6%), anemia 
      (17%), kidneys (20.8%), chronic bronchitis (14.7%), gastrointestinal (23.8%), and 
      diarrhea (20.4%). CONCLUSIONS: The current study revealed that H. pylori 
      infections were significantly higher in diabetic patients compared to controls. 
      Furthermore, T2DM patients infected with H. pylori positive reported a higher 
      prevalence rate of symptoms than H. pylori negative.
CI  - Copyright: (c) 2020 Advanced Biomedical Research.
FAU - Bener, Abdulbari
AU  - Bener A
AD  - Department of Biostatistics and Medical Informatics, Cerrahpasa Faculty of 
      Medicine, Istanbul University, Istanbul, Turkey.
AD  - Department of Evidence for Population Health Unit, Department of Epidemiology and 
      Health Sciences, The University of Manchester, Manchester, UK.
AD  - Department of Raiology and Pathology, Medipol International School of Medicine, 
      Istanbul Medipol University, Istanbul, Turkey.
FAU - Agan, Ahmet Faruk
AU  - Agan AF
AD  - Department of Gastroenterology, Medipol International School of Medicine, 
      Istanbul Medipol University, Istanbul, Turkey.
FAU - Al-Hamaq, Abdulla O A A
AU  - Al-Hamaq AOAA
AD  - Qatar Diabetic Associations and Qatar Foundation, Doha, Qatar.
FAU - Barisik, Cem Cahit
AU  - Barisik CC
AD  - Department of Raiology and Pathology, Medipol International School of Medicine, 
      Istanbul Medipol University, Istanbul, Turkey.
FAU - Ozturk, Mustafa
AU  - Ozturk M
AD  - Department of Endocrinology, Medipol International School of Medicine, Istanbul 
      Medipol University, Istanbul, Turkey.
FAU - Omer, Abdulkadir
AU  - Omer A
AD  - Department of Endocrinology, Medipol International School of Medicine, Istanbul 
      Medipol University, Istanbul, Turkey.
LA  - eng
PT  - Journal Article
DEP - 20200727
PL  - India
TA  - Adv Biomed Res
JT  - Advanced biomedical research
JID - 101586897
PMC - PMC7532836
OTO - NOTNLM
OT  - Diabetes
OT  - Helicobacter pylori infection
OT  - glycosylated hemoglobin
OT  - immunoglobulin
OT  - immunoglobulin A
OT  - immunoglobulin G
COIS- There are no conflicts of interest.
EDAT- 2020/10/20 06:00
MHDA- 2020/10/20 06:01
PMCR- 2020/07/27
CRDT- 2020/10/19 05:58
PHST- 2019/11/30 00:00 [received]
PHST- 2020/03/09 00:00 [revised]
PHST- 2020/04/14 00:00 [accepted]
PHST- 2020/10/19 05:58 [entrez]
PHST- 2020/10/20 06:00 [pubmed]
PHST- 2020/10/20 06:01 [medline]
PHST- 2020/07/27 00:00 [pmc-release]
AID - ABR-9-27 [pii]
AID - 10.4103/abr.abr_248_19 [doi]
PST - epublish
SO  - Adv Biomed Res. 2020 Jul 27;9:27. doi: 10.4103/abr.abr_248_19. eCollection 2020.